Summit completes subject enrolment in Phase III NSCLC treatment trial
The company anticipates topline data from the HARMONi trial in mid-2025.
04 October 2024
04 October 2024
The company anticipates topline data from the HARMONi trial in mid-2025.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.